Tejas Savant
Stock Analyst at Morgan Stanley
(2.15)
# 2,721
Out of 4,840 analysts
234
Total ratings
38.69%
Success rate
-5.76%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Overweight | $26 → $18 | $8.17 | +120.32% | 14 | May 19, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $136 → $100 | $80.37 | +24.42% | 8 | May 12, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $60 → $65 | $62.56 | +3.90% | 3 | May 9, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $77 → $65 | $54.28 | +19.75% | 9 | May 5, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $6.03 | +16.09% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $8.93 | +0.78% | 12 | May 5, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $17 → $10 | $7.41 | +34.95% | 13 | May 1, 2025 | |
| AVTR Avantor | Downgrades: Equal-Weight | $25 → $15 | $12.69 | +18.20% | 17 | Apr 28, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.22 | +125.23% | 13 | Mar 25, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $16 → $20 | $40.18 | -50.22% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $153.32 | +20.66% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $137.00 | +82.48% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $393.66 | +72.23% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $22.31 | +3.09% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $27.16 | +3.09% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $3.91 | +437.08% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $0.92 | +116.97% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.26 | +138.10% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $6.99 | +472.25% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $2.41 | +190.46% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.73 | +719.56% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $2.83 | +253.36% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.28 | -16.16% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $4.78 | +4.60% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.10 | +376.19% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $38.00 | +92.11% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $136.73 | +82.84% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.34 | +1,359.43% | 5 | May 12, 2022 |
10x Genomics
May 19, 2025
Maintains: Overweight
Price Target: $26 → $18
Current: $8.17
Upside: +120.32%
Illumina
May 12, 2025
Maintains: Equal-Weight
Price Target: $136 → $100
Current: $80.37
Upside: +24.42%
Tempus AI
May 9, 2025
Maintains: Overweight
Price Target: $60 → $65
Current: $62.56
Upside: +3.90%
Hologic
May 5, 2025
Maintains: Equal-Weight
Price Target: $77 → $65
Current: $54.28
Upside: +19.75%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $6.03
Upside: +16.09%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $8.93
Upside: +0.78%
NeoGenomics
May 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $7.41
Upside: +34.95%
Avantor
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $25 → $15
Current: $12.69
Upside: +18.20%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.22
Upside: +125.23%
GRAIL
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $40.18
Upside: -50.22%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $153.32
Upside: +20.66%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $137.00
Upside: +82.48%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $393.66
Upside: +72.23%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $22.31
Upside: +3.09%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $27.16
Upside: +3.09%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $3.91
Upside: +437.08%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $0.92
Upside: +116.97%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.26
Upside: +138.10%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $6.99
Upside: +472.25%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $2.41
Upside: +190.46%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.73
Upside: +719.56%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $2.83
Upside: +253.36%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.28
Upside: -16.16%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.78
Upside: +4.60%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.10
Upside: +376.19%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $38.00
Upside: +92.11%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $136.73
Upside: +82.84%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.34
Upside: +1,359.43%